Investor Presentaiton

ENHERTU DESTINY-Breast03 safety data update ASCO 2022 Highlights The data reinforce the established favorable benefit/risk profile over T-DM1 in HER2+ BC Safety update overview (Sep 7, 2021) No new safety signals were observed for T-DXd Adjudicated drug-related ILD/pneumonitis ■No Gr4/5 ILD/pneumonitis occurred in the T-DXd arm Incidence rates of AEs were similar between the T-DXd and T-DM1 arms T-DXd T-DM1 n = 257 n = 261 n (%) Any grade, n (%) Patients discontinued from study treatment 141 (54.9) 222 (85.1) Grade 1 Grade 2 Any grade TEAE 256 (99.6) 249 (95.4) Grade 3 Grade 4 Grade 3 TEAE 137 (53.3) 130 (49.8) Grade 5 Any grade serious TEAE 54 (21.0) 50 (19.2) Time to first onset, median (range), days Outcome of worst event, n (%) Grade ≥3 serious TEAE 39 (15.2) 38 (14.6) Fatal Not recovered/not resolved TEAE associated with drug discontinuation 38 (14.8) 19 (7.3) Ongoing Recovering/resolving TEAE associated with dose reduction 59 (23.0) 36 (13.8) Recovered/resolved with sequelae Recovered/resolved AE: adverse events, BC: breast cancer, TEAE, treatment-emergent adverse event. T-DXd T-DM1 n = 257 n = 261 28 (10.9) 5 (1.9) 7 (2.7) 4 (1.5) 19 (7.4) 1 (0.4) 2 (0.8) 0 0 0 0 0 181 (33-507) 289 (80-499) 0 8 (28.6) 0 2 (7.1) 2 (7.1) 16 (57.1) 1 (20.0)a 0 0 0 4 (80.0) Daiichi-Sankyo aPatient had an event of pulmonary embolism that the investigator considered to be grade 5. This was initially reported as respiratory failure but subsequently updated to pulmonary embolism. The ILD adjudication committee adjudicated this event as drug-related grade 1 ILD/ pneumonitis. The death was not evaluable for adjudication. The investigator recorded disease progression as the primary cause of death.1 1. Cortés J et al. N Engl J Med. 2022;386:1143-1154 (supplementary appendix) . 22

View entire presentation